89bio Inc. logo

ETNB

NASDAQ

89bio Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2019
$14.85+0.02 (+0.13%)
Website
News25/Ratings12

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

Price$14.85+5.63 (+60.98%)
2025-07-292025-10-29
News · 26 weeks350%
2025-10-26: 292025-11-02: 22025-11-09: 32025-11-16: 12025-11-23: 02025-11-30: 02025-12-07: 02025-12-14: 02025-12-21: 02025-12-28: 02026-01-04: 02026-01-11: 02026-01-18: 02026-01-25: 02026-02-01: 02026-02-08: 02026-02-15: 02026-02-22: 02026-03-01: 02026-03-08: 02026-03-15: 02026-03-22: 02026-03-29: 02026-04-05: 02026-04-12: 02026-04-19: 0
2025-10-262026-04-19
Mix090d

No activity.

Latest news

25 items